Hoppa till innehållet

Redeye: BioInvent Q4 2023 - Now a mid-stage clinical company

Redeye reviews BioInvent’s fourth quarter. The company now has six active clinical programs with several readouts this year, which may be transformative for the company. In particular, three projects are set to be in phase IIa during the year, of which two (BI-1206 in NHL and BI-1808) will have phase IIa readouts.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Source:MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera